Heart Disease Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Heart Disease
Scientists at Oita University release new data on heart disease
July 6th, 2008
"The efficacy and safety of sarpogrelate, a selective 5-hydroxytryptamine receptor subtype 2A antagonist, have not yet been established in bare metal coronary stenting. Accordingly, we sought to clarify whether treatment with sarpogrelate is clinically useful in bare metal coronary stenting," researchers in Oita, Japan report. "A total of 450 patients who underwent successfully planned or unplanned bare metal coronary stenting were randomly divided into the following 2 groups: the sarpogrelate (300 mg/day) plus aspirin (100 mg/day) group (group S, n = 225) and the ticlopidine (200 mg/day) plus aspirin (100 mg/day) group (group T, n = 225). Either sarpogrelate or...
Source: Heart Disease Weekly (2008-07-06)
|
